Skip to main content
DVA logo

DaVita Inc. (DVA) Stock: Price, Forecast & Analyst Target

DaVita Inc. (DVA) — MoonshotScore 76/100 (Strong band), calculated Nov 18, 2026. Price $156.24 (-3.43%), as of the Nov 19, 2026 trading session; market cap $9.83B. Expected results Feb 1, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 17.36× (cash as of Sep 30, 2026) · expected results Feb 1, 2027

$156.24 −$5.55 (-3.43%) Market Cap $9.83B

DaVita Inc. · DVA · NYSE · Healthcare · Medical - Care Facilities

Research dated 2026-09-13: DaVita delivers recurring dialysis treatments and related renal care through outpatient centers, hospitals and patients’ homes, with laboratory and integrated-care services extending the relationship beyond the dialysis chair. Its earnings path rests on treatment activity and revenue per treatment supporting cash generation while a heavy debt load limits financial flexibility.

Price as of Nov 19, 2026

Key Statistics

76 of 100

MoonshotScore v2 · DaVita (DVA)

Strong
Business Quality Solid (67)
Financial Safety Okay (55)
Valuation Cheap (80)
Growth Durability Compounding (89)
Momentum Rising (76)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite growth, at a cheap price, though quality and the balance sheet are only decent; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Solid; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.

  • quarterly revenue $3.42B (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • expected results Feb 1, 2027

Helping: an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DVA (57 recorded, newest six shown)
RecordedScoreBand
77Strong
77Strong
76Strong
76Strong
76Strong
76Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$156.24
Change on the day-3.43%
52-week range$101.00–$247.49
Market capitalisation$9.83B—
Price / earnings (trailing)13.28
Shares traded on the day988.6K
Beta (volatility vs the S&P 500)0.86

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $105, high $240, latest $156. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $240 $105 high $240 Feb 2, 2026 · Earnings results · reported above the recorded estimate · close $1091May 5, 2026 · Earnings results · reported above the recorded estimate · close $1992Aug 4, 2026 · Earnings results · reported above the recorded estimate · close $1843Oct 29, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $1884Oct 29, 2026 · Earnings results · reported above the recorded estimate · close $1885 Oct 17, 2025 Nov 19, 2026 · $156 $126Oct 17, 2025$119Oct 31, 2025$122Nov 14, 2025$120Nov 28, 2025$121Dec 12, 2025$114Dec 26, 2025$111Jan 9, 2026$108Jan 23, 2026$141Feb 6, 2026$151Feb 20, 2026$151Mar 6, 2026$149Mar 20, 2026$146Apr 2, 2026$148Apr 17, 2026$152May 1, 2026$200May 15, 2026$194May 29, 2026$209Jun 12, 2026$217Jun 26, 2026$233Jul 10, 2026$235Jul 24, 2026$184Aug 7, 2026$174Aug 21, 2026$184Sep 4, 2026$184Sep 18, 2026$179Oct 2, 2026$187Oct 16, 2026$188Oct 30, 2026$175Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • We now expect IKC to deliver at least $65 million of adjusted operating income in 2026, an increase of at least $25 million over the prior guidance.

    Javier Rodriguez · Statement from

  • We now expect this year's IKC adjusted operating income to be at least $65 million, representing a $45 million improvement over last year and a $25 million improvement over our prior guidance.

    Joel Ackerman · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for DaVita (DVA): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Strong
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Strong
ROE Negative
Gross Margin Neutral

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is DaVita (DVA), and what does it report?

Short answer · as of

DaVita is primarily a kidney-care operator, not a general medical-facilities business. It treats chronic kidney failure through outpatient dialysis centers, provides acute dialysis in hospitals and home-based care, runs diagnostic laboratories, and supports other dialysis facilities and physicians.

Reported revenue is concentrated in domestic dialysis and related laboratory services. The broader portfolio includes integrated kidney care, vascular-access interventions, clinical research and international clinics, but dialysis treatment activity remains the core economic unit.

2 · Latest results

What do the latest results show for DaVita (DVA)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $3.42B.

The latest completed year paired revenue growth with lower net income. More recent results improved sharply from the preceding period: revenue recovered, while gross profit, operating income, net income and diluted earnings per share all advanced. Revenue and earnings per share also cleared consensus again.

Treatment activity and revenue earned per treatment form the operating bridge. Management expects treatment growth near the upper end of its prior range, yet expects full-period revenue-per-treatment growth to moderate from the pace recorded earlier in the year. Management also expects international operations and Integrated Kidney Care to contribute to operating-income growth.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$3.58B Sep 30, 2026
Latest quarter · SG&A
$408.70M Sep 30, 2026
Latest quarter · FMP standardized operating result
$499.25M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$3.58BNot available$408.70M$499.25M
Jun 30, 2026$3.55BNot available$423.46M$570.82M
Mar 31, 2026$3.42BNot available$421.91M$481.89M
Dec 31, 2025$3.62BNot available$472.36M$551.21M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$3.58B Oct 29, 2026
Latest report · revenue estimate
$3.52B Oct 29, 2026
Latest report · revenue vs estimate
Above estimate Oct 29, 2026
Latest report · EPS vs estimate
Above estimate Oct 29, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 29, 2026$3.58B$3.52B$3.8200$3.5700
Aug 4, 2026$3.55B$3.50B$4.0200$3.8800
May 5, 2026$3.42B$3.36B$2.8700$2.4100
Feb 2, 2026$3.62B$3.51B$3.4000$3.2400
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$3.42B$150M$2.04 (diluted)
Q4 FY2025$3.62B$234M$2.45 (diluted)
Q1 FY2026$3.42B$198M$2.87 (diluted)
Q2 FY2026$3.55B$265M$4.02 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for DaVita (DVA)?

Short answer

Cash and short-term investments were $566.30M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $518.83M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operations generated positive cash flow throughout the reported series, and cash generation remained positive after capital spending. That gives DaVita an internally funded base for maintaining its treatment network.

Debt substantially exceeds cash and investments, while cash and short-term investments have declined across the reported window. Near-term liquidity ratios indicate coverage of near-term obligations, but the negative debt-to-equity reading makes conventional leverage comparisons less informative. Stalling treatment growth alongside moderating revenue per treatment would weaken the cash available to manage that leverage.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.68 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$518.83M Sep 30, 2026
Previous quarter · operating cash flow
$490.07M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$518.83M−$159.49M
Jun 30, 2026$490.07M−$169.82M
Mar 31, 2026$320.83M−$102.02M
Dec 31, 2025$540.73M−$145.43M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at DaVita (DVA)?

Short answer · as of

The next earnings report is expected on Feb 1, 2027.

At the scheduled earnings release, compare treatment activity with management’s improved volume trajectory and test whether revenue per treatment is moderating toward the full-period outlook. Consensus also implies sequential moderation in revenue and earnings per share, making the direction of operating profit particularly informative.

Integrated Kidney Care deserves separate attention. Management expects timing in that business to drive a sizable step-up in adjusted operating income between the coming reporting periods, while international operations and Integrated Kidney Care are each expected to add to full-period profit growth.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. We still anticipate full year free cash flow between $1 billion and $1.25 billion.

    Joel Ackerman ·

2 more statements are quoted under Upcoming events

What the records here don't tell us

  • The newest quarter held here (Q3 FY2025) was filed Oct 29, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does DaVita compare with its peers?

Short answer

DaVita's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

DaVita differs from diversified care-facility operators because demand centers on repeated, medically necessary dialysis treatments rather than broad hospital or clinic utilization. The same kidney-care relationship can span an outpatient center, a hospital, the patient’s home and related laboratory work.

Integrated Kidney Care adds chronic-disease management and risk-based care arrangements to the treatment network. That broadens DaVita’s exposure beyond reimbursement for dialysis sessions, although reported revenue remains concentrated in domestic dialysis and related laboratory services.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Tenet Healthcare Corporation (THC) Same industry, near in market value$271.34 Nov 18, 2026$21.6B94 5-pillar Nov 18, 2026
LifeStance Health Group, Inc. (LFST) Same industry, near in market value$13.77 Nov 18, 2026$5.24B92 5-pillar Nov 18, 2026
Universal Health Services, Inc. (UHS) Named competitor$186.07 Nov 18, 2026$10.7B91 5-pillar Nov 18, 2026
Chemed Corporation (CHE) Same industry, near in market value$546.72 Nov 18, 2026$7.09B85 5-pillar Nov 18, 2026
Option Care Health, Inc. (OPCH) Same industry, near in market value$31.71 Nov 18, 2026$4.75B85 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Named competitor$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Encompass Health Corporation (EHC) Same industry, near in market value$132.25 Nov 19, 2026$13.0B81 5-pillar Nov 18, 2026
Fresenius Medical Care AG & Co. KGaA (FMS) Same industry, near in market value$20.95 Nov 18, 2026$10.9B80 5-pillar Nov 18, 2026
DaVita (DVA) — this page$156.24$9.83B76
The Ensign Group, Inc. (ENSG) Named competitor$176.59 Nov 19, 2026$10.3B74 5-pillar Nov 18, 2026
Solventum Corporation (SOLV) Same industry, near in market value$86.48 Nov 18, 2026$14.7B66 5-pillar Nov 18, 2026
BioMarin Pharmaceutical Inc. (BMRN) Named competitor$61.43 Nov 18, 2026$11.9B58 5-pillar Nov 18, 2026
MiniMed Group, Inc. Common Stock (MMED) Same industry, near in market value$16.26 Nov 19, 2026$4.57B38 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$215.00 – $287.00
Consensus target
$238.50
Median target
$222.00

Consensus record · Captured .

Measured against a quoted price of $156.24 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 15, 2026

Transactions
26
Identified insiders
13
Purchases
0
Sales
6
Other transactions
20

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
92.9% Period end Sep 30, 2026
Previous quarter · ownership
91.7% Prior to period end Sep 30, 2026
Reporting holders
659 Period end Sep 30, 2026
Previous quarter · holders
668 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Berkshire Hathaway INC28,697,229
Blackrock, INC.2,733,890
Vanguard Capital Management LLC2,259,222
Morgan Stanley1,641,878
Vanguard Portfolio Management LLC1,573,788

Tracked investors

Which of the 16 named investors we follow held DVA in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Berkshire HathawayWarren Buffett, Greg AbelQ3 20261.65%$5.02BTrimmed −0.6% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about DaVita (DVA)?

Read these with our analysis →

What Investors Ask About DaVita (DVA) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How does DaVita earn revenue from outpatient dialysis?

DaVita earns revenue by delivering recurring dialysis treatments and related laboratory services. Treatment activity and revenue received per treatment are therefore the key operating levers.

Why does DaVita track revenue per treatment?

Revenue per treatment shows how reimbursement and service mix translate each dialysis session into revenue. Management expects its growth to moderate from the pace recorded earlier in the year, even as treatment activity trends toward the stronger end of prior expectations.

What does DaVita Integrated Kidney Care add to dialysis?

Integrated Kidney Care extends DaVita into chronic-disease management and risk-based care arrangements. Management expects the business to contribute to profit growth, with timing shaping the progression of operating income.

Is Berkshire Hathaway a major DaVita shareholder?

Berkshire Hathaway is the largest named institutional holder. Institutional investors collectively own most of the company, although their aggregate ownership edged lower in the latest disclosed period.

What is the DVA stock price today?

The last price recorded for DaVita Inc. (DVA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the DVA price target?

The analyst consensus price target for DaVita Inc. (DVA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 77 figures on this page — 2 from SEC filings and earnings calls, 68 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Management outlook — dated call excerpts; Cash, investments and debt
  • 1. What is DaVita (DVA), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for DaVita (DVA)?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for DaVita (DVA)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • 4. What should you watch next at DaVita (DVA)?: Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • 5. How does DaVita compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: How does DaVita earn revenue from outpatient dialysis?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: Why does DaVita track revenue per treatment?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • FAQ: What does DaVita Integrated Kidney Care add to dialysis?: Business description; Management outlook — dated call excerpts
  • FAQ: Is Berkshire Hathaway a major DaVita shareholder?: Largest 5 institutional holders; Institutional ownership (13F)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold DVA

Funds in our ETF coverage that list DVA among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
The Obesity ETF (SLIM)4.55%
XHS ETF2.60%
QSY ETF1.67%
DWSH ETF1.36%
AdvisorShares Insider Advantage ETF (SURE)1.31%